BIVIW

Biovie Inc

• Reuters·04/01 22:27

  BioVie publishes corporate presentation on bezisterim pipeline catalysts in Parkinson’s, Long Covid

• Reuters·03/12 12:05

  BioVie to present SUNRISE-PD bezisterim poster at AD/PD 2026

• Reuters·02/23 13:04

  BioVie to Host Live Investor Webinar and Q&A Session with CEO Cuong Do

• Reuters·02/12 13:01

  BioVie Inc. Announces Phase 2 and 3 Clinical Trials of Bezisterim for Alzheimer's and Long COVID

• Reuters·01/26 11:03

  OPTION THERAPEUTICS INC SAYS THINKEQUITY IS THE UNDERWRITER TO IPO

• Reuters·01/10 18:53

  BioVie Inc. unveils new data on bezisterim's potential in Parkinson's and Alzheimer's therapies

• Reuters·01/08 13:02

  BioVie Completes Enrollment for Phase 2 SUNRISE-PD Trial Testing Bezisterim in Early Parkinson’s Disease

• Reuters·01/08 13:00

  BIOVIE COMPLETES ENROLLMENT IN PHASE 2 SUNRISE-PD TRIAL IN EARLY PARKINSON’S DISEASE

• Reuters·01/08 13:00

  BIOVIE INC - TOPLINE RESULTS FROM SUNRISE-PD TRIAL EXPECTED IN 1H 2026

• Reuters·12/08/2025 21:05

  Halozyme Therapeutics Elects Jim Lang to Board of Directors

• Reuters·10/28/2025 15:20

  BioVie Inc. Files Initial Statement of Beneficial Ownership for Director Kameel D. Farag

• Reuters·10/27/2025 22:36

  BioVie Inc. Files Initial Beneficial Ownership Statement for Director Amy Suzon Chappell

• Reuters·09/25/2025 21:27

  BioVie Inc. Announces Date for Upcoming Virtual Annual Stockholders Meeting

• Reuters·08/15/2025 21:06

  BioVie Inc. Reports Net Loss of $17.5 Million for Fiscal Year Ending June 30, 2025; R&D Expenses Drop by $13.8 Million

• Reuters·08/13/2025 20:06

  Cuong V Do, President & CEO of BioVie Inc., Reports Acquisition of Common Shares